#LCSM Transcript

Healthcare social media transcript of the #LCSM hashtag.
().
See #LCSM Influencers/Analytics.

Sign up for FREE Symplur Account and Get
  • Create Transcripts with Custom Dates
  • Get Custom Influencer Lists
  • 3x Hashtag Search Results
Sign Up Now
ProfileTweet
Bob Steele @steele_bob
@GERI1365 Great pic! #lcsm
NCI Cancer Stats @NCICancerStats
Death rates for #LungCancer have been falling on average 2.5% each year between 2005-2014. Learn more: https://t.co/JV6sVLEnLw #LCSM https://t.co/XpVifiPiDV
Brendon Stiles @BrendonStilesMD
You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Bob Steele @steele_bob
RT @JFreemanDaily: I've been sifting through 2000+ unique #WCLC2017 tweets--no way we'll cover everything in 60 min! But we'll have fun try…
Brendon Stiles @BrendonStilesMD
To join, enter the URL “tchat.io” in your browser and type in #lcsm #lcsm
Hossen Mahmud, MD @DrHMahmudMD
RT @NCICancerStats: Death rates for #LungCancer have been falling on average 2.5% each year between 2005-2014. Learn more:…
Faces of Lung Cancer @LungCancerFaces
Can't wait to see you again! DC here we come. RT @dennycee: Good evening. MI in the house. Just confirmed airbnb for 11/2 #433aday #lcsm
Brendon Stiles @BrendonStilesMD
We'll get started in a few minutes -- please take a moment to introduce yourselves #lcsm
Eden Lake @EdenLake
Hope to merge my #lungcancer experience with my #photojournalism in a #facesoflungcancer photo series over the next year. #lcsm
Anita Figueras @scifiknitter
Anita, currently in NYC. First scan results from erlotinib/trametinib combo clinical trial tomorrow. 😮 #lcsm
Paula A @paulalv
#lcsm Hi everyone
Diane @diianeee
hello :) #lcsm
Brendon Stiles @BrendonStilesMD
Good evening! Looking forward to a great chat and to hearing about all the #lcsm news from #wclc2017. #lcsm
Paula A @paulalv
@dennycee #lcsm yay, we can't wait to see you
Black Tina @bankszina
#lcsm
Brendon Stiles @BrendonStilesMD
I will announce FOUR topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to follow. #lcsm
Eden Lake @EdenLake
Eden, finished 3rd round of #immunotherapy last night. Surgery was 16 months ago. #nsclc #lcsm
Faces of Lung Cancer @LungCancerFaces
Deana Hendrickson in Los Angeles here. Looking forward to tonight's chat. #lcsm
Brendon Stiles @BrendonStilesMD
I’m your moderator Brendon Stiles, a thoracic surgeon, lung cancer researcher, and patient advocate. #lcsm
Nay @ChancesR3
NaomiF here in L A. Fresh fr USC Norris where husband evaluated today for durvalumab and AZD 6738 clinical trial. 5th line Hope! #lcsm
Ian Pereira @IanJPereira
RT @lcsmchat: TODAY! #LCSM Chat Th 10/19: World Conference on Lung Cancer #WCLC2017 Wrap-Up: https://t.co/oHJRmseSrK… Join us!…
Brendon Stiles @BrendonStilesMD
We’ll start with Topic T1 in a minute. Great to have such a diverse group here! Thanks to everyone for joining. #lcsm
Eden Lake @EdenLake
@scifiknitter All good wishes my friend #lcsm
Janet Freeman-Daily @JFreemanDaily
Janet Freeman-Daily in Seattle. It's fall. It's gray. It will be raining for the next six months. Time to visit with #LCSM tweeps!
Brendon Stiles @BrendonStilesMD
T1. Why is the annual World Conference on Lung Cancer such an important meeting? #lcsm
Faces of Lung Cancer @LungCancerFaces
@ChancesR3 So excited for you guys #lcsm
Bob Steele @steele_bob
RT @JFreemanDaily: Janet Freeman-Daily in Seattle. It's fall. It's gray. It will be raining for the next six months. Time to visit with #LC
#LCSM Chat @lcsmchat
RT @GERI1365: Before we start have to share my 1st lil grandson’s 1st School Picture, your smile for today #LCSM https://t.co/eJTV8Wj9Ft
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T1. Why is the annual World Conference on Lung Cancer such an important meeting? #lcsm
Brendon Stiles @BrendonStilesMD
T1. #WCLC2017 has increasingly become gathering place that bridges all disciplines treating lung cancer – unique crosstalk. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: I've been sifting through 2000+ unique #WCLC2017 tweets--no way we'll cover everything in 60 min! But we'll have fun try…
Danielle Pardue @Actorielle
Sorry I'm a little late, my friends...but I have pizza! #LCSM
John from Alabama @JohnLPender
here 🙋‍♂️ #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: To join, enter the URL “tchat.io” in your browser and type in #lcsm #lcsm
#LCSM Chat @lcsmchat
RT @EdenLake: Hope to merge my #lungcancer experience with my #photojournalism in a #facesoflungcancer photo series over the next year. #lc
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Good evening! Looking forward to a great chat and to hearing about all the #lcsm news from #wclc2017. #lcsm
Brendon Stiles @BrendonStilesMD
Good luck! RT @ChancesR3: NaomiF here in L A. Fresh fr USC Norris where husband evaluated today for durvalumab. Hope! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I will announce FOUR topics (T1 T2 etc). Please label your responses with T1, T2, etc to make transcript easier to fol…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: I’m your moderator Brendon Stiles, a thoracic surgeon, lung cancer researcher, and patient advocate. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: You can read about how to participate in the chat at https://t.co/93SziNyHT6 #lcsm
Deb Smith 🍀 @debsmithbeach
#LCSM Deb from NH here.
#LCSM Chat @lcsmchat
RT @ChancesR3: NaomiF here in L A. Fresh fr USC Norris where husband evaluated today for durvalumab and AZD 6738 clinical trial. 5th line H…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Why is the annual World Conference on Lung Cancer such an important meeting? #lcsm
Brendon Stiles @BrendonStilesMD
T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative care #lcsm
Janet Freeman-Daily @JFreemanDaily
T1: #WCLC2017 was gathering of 7000 people from 85 countries, focused on #lungcancer detection, treatment & care #LCSM https://t.co/SUqdhxtj9n
Eden Lake @EdenLake
T1 bringing diverse voices, researchers, approaches and methodologies into one place to stimulate new approaches & pathways important #lcsm
Nay @ChancesR3
@BrendonStilesMD Thanks @BrendonStilesMD !#lcsm
Brendon Stiles @BrendonStilesMD
T1. - and weaves #science into all. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative c…
Janet Freeman-Daily @JFreemanDaily
T1: @IASLC CEO Dr Fred Hirsch shared some highlights #WCLC2017 before the conference began #LCSM https://t.co/sWydIbHaBz https://t.co/gOjOmAoVKS
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: #WCLC2017 was gathering of 7000 people from 85 countries, focused on #lungcancer detection, treatment & care…
Bob Steele @steele_bob
RT @EdenLake: T1 bringing diverse voices, researchers, approaches and methodologies into one place to stimulate new approaches & pathways…
Nay @ChancesR3
@LungCancerFaces Thanks so much D! Hope is addictive. #lcsm
#LCSM Chat @lcsmchat
RT @EdenLake: T1 bringing diverse voices, researchers, approaches and methodologies into one place to stimulate new approaches & pathways…
Bob Steele @steele_bob
RT @JFreemanDaily: T1: @IASLC CEO Dr Fred Hirsch shared some highlights #WCLC2017 before the conference began #LCSM
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative c…
Brendon Stiles @BrendonStilesMD
T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and patients/advocates! #lcsm
Faces of Lung Cancer @LungCancerFaces
@IntrovertinNC Hence the "introvert" moniker. Welcome. #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: T1: @IASLC CEO Dr Fred Hirsch shared some highlights #WCLC2017 before the conference began #LCSM
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and pat…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and pat…
Brendon Stiles @BrendonStilesMD
@LungCancerFaces @IntrovertinNC Great use of "hence" on twitter. #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and pat…
Anita Figueras @scifiknitter
@Actorielle It's a honeymoon tweet chat with @Actorielle ! 🎉 #lcsm
Black Tina @bankszina
#lcsm currently waiting to get into clinical trial w/Nivolumab and cimavax
Sarai Souza @kingskid9984
RT @EdenLake: Eden, finished 3rd round of #immunotherapy last night. Surgery was 16 months ago. #nsclc #lcsm
Brendon Stiles @BrendonStilesMD
T1. I love that #WCLC2017 explores new cutting edge technology/science, but keeps everything in context of clinical utility. #lcsm
Faces of Lung Cancer @LungCancerFaces
@bankszina Best hopes! #lcsm
Shankar Siva @_ShankarSiva
T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo chamber #LCSM
Anita Figueras @scifiknitter
RT @BrendonStilesMD: T1. #WCLC2017 runs the gamut of lung cancer – prevention, early diagnosis, surgery, radiation, oncology, palliative c…
Faces of Lung Cancer @LungCancerFaces
@scifiknitter @Actorielle Now that's what I call dedication! #lcsm
Bob Steele @steele_bob
RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo…
Janet Freeman-Daily @JFreemanDaily
T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm
Tiffini Joseph @Smiles4Nana
T1: what an amazing collaboration! #lcsm https://t.co/5215Tq8vmE
Brendon Stiles @BrendonStilesMD
This is key to staying honest. RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - #LCSM
Hossen Mahmud, MD @DrHMahmudMD
RT @Smiles4Nana T1: what an amazing collaboration! #lcsm https://t.co/svoUhHlbLu
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. I love that #WCLC2017 explores new cutting edge technology/science, but keeps everything in context of clinical ut…
#LCSM Chat @lcsmchat
RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo…
Eden Lake @EdenLake
Congrats @Actorielle #lcsm
Brendon Stiles @BrendonStilesMD
T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality care everywhere.#lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm
#LCSM Chat @lcsmchat
RT @Smiles4Nana: T1: what an amazing collaboration! #lcsm https://t.co/5215Tq8vmE
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: This is key to staying honest. RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other discipl…
colleen ziegler @ZieglerColleen
#lcsm joining a little late Colleen in Rochester
Janet Freeman-Daily @JFreemanDaily
T1: I think many #WCLC2017 participants are presently either on planes en route to home, or recovering from jet lag ... #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality…
Brendon Stiles @BrendonStilesMD
Important question coming up next. #lcsm
Eden Lake @EdenLake
RT @JFreemanDaily: T1: @IASLC CEO Dr Fred Hirsch shared some highlights #WCLC2017 before the conference began #LCSM
Ian Pereira @IanJPereira
@BrendonStilesMD Hi #lcsm!
Mark Dimor @MarksPhone
#lcsm What makes a conference valuable & important is engagement/commitment/focus of those in need of knowledge, care, & hope
Tom Varghese Jr. MD @TomVargheseJr
RT @Smiles4Nana: T1: what an amazing collaboration! #lcsm https://t.co/5215Tq8vmE
Alvaro Carrascal @CarrascalAlvaro
RT @NCICancerStats: Death rates for #LungCancer have been falling on average 2.5% each year between 2005-2014. Learn more:…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality…
Brendon Stiles @BrendonStilesMD
T2. What is the role of patients and advocates at this meeting? #lcsm
Bob Steele @steele_bob
RT @MarksPhone: #lcsm What makes a conference valuable & important is engagement/commitment/focus of those in need of knowledge, care, & ho…
Danielle Pardue @Actorielle
RT @JFreemanDaily: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm
Paige Molinari @paisley6681
RT @BrendonStilesMD: 11 minutes until #lcsm chat. Please join us! #lcsm
Danielle Pardue @Actorielle
RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other disciplines - it’s too easy to get caught in your own echo…
Janet Freeman-Daily @JFreemanDaily
T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yNRqNPxpZc
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T1. I love that #WCLC2017 explores new cutting edge technology/science, but keeps everything in context of clinical ut…
Clive Peedell @cpeedell
T1 #WCLC provides cutting edge summaries of global lung cancer research from prevention to palliation, from politics to hard science #LCSM
Eden Lake @EdenLake
RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yN…
Brendon Stiles @BrendonStilesMD
This. RT @MarksPhone: #lcsm What makes a conference valuable & important is engagement/commitment/focus..of knowledge, care, & hope
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T1. @IASLC also taking lead in evaluating clinical/pathologic guidelines – a great job emphasizing access and quality…
Danielle Pardue @Actorielle
RT @MarksPhone: #lcsm What makes a conference valuable & important is engagement/commitment/focus of those in need of knowledge, care, & ho…
Janet Freeman-Daily @JFreemanDaily
T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungcancer outcomes #LCSM
Bob Steele @steele_bob
RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yN…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T1: I think many #WCLC2017 participants are presently either on planes en route to home, or recovering from jet lag ...…
#LCSM Chat @lcsmchat
RT @MarksPhone: #lcsm What makes a conference valuable & important is engagement/commitment/focus of those in need of knowledge, care, & ho…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. What is the role of patients and advocates at this meeting? #lcsm
Mark Dimor @MarksPhone
@BrendonStilesMD #lcsm Listen, learn, share, question, support and advocate.
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yN…
Tom Varghese Jr. MD @TomVargheseJr
RT @MarksPhone: #lcsm What makes a conference valuable & important is engagement/commitment/focus of those in need of knowledge, care, & ho…
Gina @EAustin1969
Lurking #lcsm
Janet Freeman-Daily @JFreemanDaily
T2: #lungcancer patients and advocates were among the featured voices on Twitter for #WCLC2017 #LCSM https://t.co/yPzrx8hOcu
Brendon Stiles @BrendonStilesMD
Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.co/zm45iueneF
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T2. What is the role of patients and advocates at this meeting? #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yN…
Danielle Pardue @Actorielle
RT @cpeedell: T1 #WCLC provides cutting edge summaries of global lung cancer research from prevention to palliation, from politics to hard…
Brendon Stiles @BrendonStilesMD
T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #lcsm
Anita Figueras @scifiknitter
RT @JFreemanDaily: T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungca
Danielle Pardue @Actorielle
RT @JFreemanDaily: T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungca
Brendon Stiles @BrendonStilesMD
T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. Amazing breadth! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #…
Faces of Lung Cancer @LungCancerFaces
T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto next year. #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: T2: #lungcancer patients and advocates were among the featured voices on Twitter for #WCLC2017 #LCSM https://t.co/yPzrx8…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.c…
Jill @jillfeldman4
@ivybelkins & I in Tokyo sending our hello! #WCLC2017 great learning & connecting. Exciting time for lc research #LCSM
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #…
Anita Figueras @scifiknitter
RT @BrendonStilesMD: Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.c…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. A…
Bob Steele @steele_bob
RT @LungCancerFaces: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto…
Tiffini Joseph @Smiles4Nana
@BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm
Danielle Pardue @Actorielle
RT @LungCancerFaces: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto…
Sarah B @gilhuss
RT @LungCancerFaces: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto…
BUY FOLLO₩ERS ,pod @juleedelosange1
RT @LungCancerFaces: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto…
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T1. Includes incredibly broad group of stakeholders: MDs, scientists, nurses, industry, government officials – and pat…
Eden Lake @EdenLake
Welcome! @jillfeldman4 @ivybelkins #lcsm
Brendon Stiles @BrendonStilesMD
T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. everywhere else! #lcsm
#LCSM Chat @lcsmchat
RT @cpeedell: T1 #WCLC provides cutting edge summaries of global lung cancer research from prevention to palliation, from politics to hard…
Eden Lake @EdenLake
RT @Smiles4Nana: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T2: #WCLC2017 "patient advocacy" track had presentations on patient/advocate research and initiatives to improve #lungca
#LCSM Chat @lcsmchat
RT @MarksPhone: @BrendonStilesMD #lcsm Listen, learn, share, question, support and advocate.
Danielle Pardue @Actorielle
RT @Smiles4Nana: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T2: #lungcancer patients and advocates were among the featured voices on Twitter for #WCLC2017 #LCSM https://t.co/yPzrx8…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. ev…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. A…
#LCSM Chat @lcsmchat
RT @LungCancerFaces: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto…
Tom Varghese Jr. MD @TomVargheseJr
RT @BrendonStilesMD: This is key to staying honest. RT @_ShankarSiva: T1 - I think #WCLC2017 is great to learn more about the other discipl…
Brendon Stiles @BrendonStilesMD
@Smiles4Nana This is true. Easy to get caught up in self importance at meetings. Have to remember all about patients. #lcsm
#LCSM Chat @lcsmchat
RT @jillfeldman4: @ivybelkins & I in Tokyo sending our hello! #WCLC2017 great learning & connecting. Exciting time for lc research #LCSM
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. ev…
Ian Pereira @IanJPereira
@BrendonStilesMD Great to hear that patients attended #WCLC2017! #lcsm
Eden Lake @EdenLake
RT @BrendonStilesMD: @Smiles4Nana This is true. Easy to get caught up in self importance at meetings. Have to remember all about patients…
Pet Door Pro @petd0orpro
RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to enable patients/advocates to attend #WCLC2017 #LCSM https://t.co/yN…
Brendon Stiles @BrendonStilesMD
@jillfeldman4 @ivybelkins What time is it there!? #lcsm
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T2. What is the role of patients and advocates at this meeting? #lcsm
Faces of Lung Cancer @LungCancerFaces
@jillfeldman4 @ivybelkins You ladies are having too much fun! I love all your photos/tweets! #lcsm
Janet Freeman-Daily @JFreemanDaily
T2: Example: @GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session #LCSM #LCAM https://t.co/Q8c3ERiU8G
Charlie Mac @nancyke71102175
RT @cpeedell: T1 #WCLC provides cutting edge summaries of global lung cancer research from prevention to palliation, from politics to hard…
Ian Pereira @IanJPereira
RT @BrendonStilesMD: Share this! RT @JFreemanDaily: T2: @IASLC offered Patient Advocate Travel Awards to attend #WCLC2017 #LCSM https://t.c…
Janet Freeman-Daily @JFreemanDaily
RT @IASLC: .@GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session on raising awareness and building…
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T2. @IASLC and #WCLC2017 are totally committed to patients/advocacy. Multiple advocacy sessions throughout meeting. #…
Brendon Stiles @BrendonStilesMD
@JFreemanDaily @GoldmanLisa Great example of patients taking an active role. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @Smiles4Nana This is true. Easy to get caught up in self importance at meetings. Have to remember all about patients…
Shankar Siva @_ShankarSiva
T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cancer? #LCSM
Danielle Pardue @Actorielle
RT @JFreemanDaily: T2: Example: @GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session #LCSM #LCAM https://t.co/…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @Smiles4Nana This is true. Easy to get caught up in self importance at meetings. Have to remember all about patients…
#LCSM Chat @lcsmchat
RT @IJohnPereira: @BrendonStilesMD Great to hear that patients attended #WCLC2017! #lcsm
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T2. Cover patient perspectives, psychosocial needs, patient reported outcomes, patient barriers, addressing stigma. A…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T2: Example: @GoldmanLisa, #ROS1 LC survivor, talks on ROS1ders in #WCLC2017 advocacy session #LCSM #LCAM https://t.co/…
Danielle Pardue @Actorielle
RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cance…
Geri Massa @GeriGerim13
I would love to be able to attend webinars live, or have library #LCSM
Janet Freeman-Daily @JFreemanDaily
T2: Patients network with each other and experts in their type of cancer at #WCLC2017 #LCSM https://t.co/TEVipzZh7P
Brendon Stiles @BrendonStilesMD
@_ShankarSiva Yes! We worry about this in T4 though! #lcsm
Hossen Mahmud, MD @DrHMahmudMD
We have to remember about LC patients, particularly NSCLC and SCLC patients during the meeting which we participate. #LCSM
Bob Steele @steele_bob
RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cance…
Eden Lake @EdenLake
RT @GERI1365: I would love to be able to attend webinars live, or have library #LCSM
Ian Pereira @IanJPereira
@BrendonStilesMD @JFreemanDaily @IASLC Interesting model to improve patient engagement at meetings! #lcsm #wclc2017
Brendon Stiles @BrendonStilesMD
T2 was great and got the crowd going. Here comes T3. #lcsm
Eden Lake @EdenLake
RT @JFreemanDaily: T2: Patients network with each other and experts in their type of cancer at #WCLC2017 #LCSM https://t.co/TEVipzZh7P
Lung Cancer Sux @LungCancerSux
Thanks for all of the great representation! #LCSM
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T2. Interesting to understand differences in patient perspective/advocacy Asia v. USA v. Europe v. Latin America v. ev…
#LCSM Chat @lcsmchat
RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cance…
Bob Steele @steele_bob
RT @GERI1365: I would love to be able to attend webinars live, or have library #LCSM
#LCSM Chat @lcsmchat
RT @GERI1365: I would love to be able to attend webinars live, or have library #LCSM
Danielle Pardue @Actorielle
RT @JFreemanDaily: T2: Patients network with each other and experts in their type of cancer at #WCLC2017 #LCSM https://t.co/TEVipzZh7P
Brendon Stiles @BrendonStilesMD
T3. What is new in cancer screening and early stage lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T2: Patients network with each other and experts in their type of cancer at #WCLC2017 #LCSM https://t.co/TEVipzZh7P
Danielle Pardue @Actorielle
RT @DrHMahmud: We have to remember about LC patients, particularly NSCLC and SCLC patients during the meeting which we participate. #LCSM
#LCSM Chat @lcsmchat
RT @DrHMahmud: We have to remember about LC patients, particularly NSCLC and SCLC patients during the meeting which we participate. #LCSM
Ian Pereira @IanJPereira
RT @Smiles4Nana: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm
#LCSM Chat @lcsmchat
RT @IJohnPereira: @BrendonStilesMD @JFreemanDaily @IASLC Interesting model to improve patient engagement at meetings! #lcsm #wclc2017
Brendon Stiles @BrendonStilesMD
T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. What is new in cancer screening and early stage lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. What is new in cancer screening and early stage lung cancer? #lcsm
Eden Lake @EdenLake
RT @BrendonStilesMD: T3. What is new in cancer screening and early stage lung cancer? #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm
Ian Pereira @IanJPereira
@Smiles4Nana @BrendonStilesMD Curious to hear thoughts on how patient advocacy is received at these meetings. Moving forward? #lcsm #wclc2017 T2
Brendon Stiles @BrendonStilesMD
T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Project. #lcsm
Tiffini Joseph @Smiles4Nana
RT @BrendonStilesMD: T3. What is new in cancer screening and early stage lung cancer? #lcsm
Danielle Pardue @Actorielle
RT @IJohnPereira: @Smiles4Nana @BrendonStilesMD Curious to hear thoughts on how patient advocacy is received at these meetings. Movin…
Aidan @gizmuslo
RT @Smiles4Nana: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Pro…
Brendon Stiles @BrendonStilesMD
One key to making screening work is getting the right populations to actually be screened! #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Pro…
Dr. David Tom Cooke @DavidCookeMD
T3 What was the engagement innovation in ID 10643? #LCSM https://t.co/kJKic8zBkn
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm
#LCSM Chat @lcsmchat
RT @IJohnPereira: @Smiles4Nana @BrendonStilesMD Curious to hear thoughts on how patient advocacy is received at these meetings. Movin…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Good lessons on engagement of high risk populations for screening (ID 10643). Overview -Liverpool Healthy Lung Pro…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm
Geri Massa @GeriGerim13
T3: would be great if it was part of normal testing ex. Mammograms, etc #lcsm
Anita Figueras @scifiknitter
RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm
Faces of Lung Cancer @LungCancerFaces
THIS RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm
Brendon Stiles @BrendonStilesMD
T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm
Tiffini Joseph @Smiles4Nana
@BrendonStilesMD I feel the screening should include those with family hx, not just older, heavy smokers. #lcsm
Ian Pereira @IanJPereira
RT @LungCancerFaces: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto…
Janet Freeman-Daily @JFreemanDaily
T3: #WCLC2017 had some great presentations on how to decide whether a lung nodule required action #lcsm
Ian Pereira @IanJPereira
@LungCancerFaces @IASLC Me, too :) #lcsm #wclc2017 #wclc2018
tracee burnette @bigbird4730
RT @GERI1365: I would love to be able to attend webinars live, or have library #LCSM
Brendon Stiles @BrendonStilesMD
T3. Also strong focus on quality assurance and training for CT screening. #lcsm
Faces of Lung Cancer @LungCancerFaces
@GERI1365 Once we develop the right kind of test for the lower risk populations. #lcsm
Tiffini Joseph @Smiles4Nana
RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm
Dr. David Tom Cooke @DavidCookeMD
T3 I think it is a provider (doctor) issue. #LCSM https://t.co/47V22OEmaE
Danielle Pardue @Actorielle
RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm
Anita Figueras @scifiknitter
RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm
Danielle Pardue @Actorielle
RT @GERI1365: T3: would be great if it was part of normal testing ex. Mammograms, etc #lcsm
#LCSM Chat @lcsmchat
RT @DavidCookeMD: T3 What was the engagement innovation in ID 10643? #LCSM https://t.co/kJKic8zBkn
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm
Danielle Pardue @Actorielle
RT @Smiles4Nana: @BrendonStilesMD I feel the screening should include those with family hx, not just older, heavy smokers. #lcsm
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T3. I loved the idea of presenting a patient’s perspective on CT screening. Thanks @findlungcancer! #lcsm
Danielle Pardue @Actorielle
RT @DavidCookeMD: T3 I think it is a provider (doctor) issue. #LCSM https://t.co/47V22OEmaE
Brendon Stiles @BrendonStilesMD
T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical standards. #lcsm
Tiffini Joseph @Smiles4Nana
@DavidCookeMD T3: agreed. General practitioners especially don’t have a full understanding of who is at risk #lcsm
Sarah Elizabeth @saraheliz1
RT @BrendonStilesMD: One key to making screening work is getting the right populations to actually be screened! #lcsm
Brendon Stiles @BrendonStilesMD
@Smiles4Nana Clearly we have to identify risk factors other than just smoking. #lcsm
Sarah Elizabeth @saraheliz1
RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm
Janet Freeman-Daily @JFreemanDaily
.@findlungcancer had MANY great tweets about lung cancer screening presentations--search for her tweets #lcsm
Hossen Mahmud, MD @DrHMahmudMD
It is helpful for saving lives, if we screen high-risk LC patients. #LCSM
Tiffini Joseph @Smiles4Nana
@BrendonStilesMD Clearly 😉 #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical…
Danielle Pardue @Actorielle
RT @Smiles4Nana: @DavidCookeMD T3: agreed. General practitioners especially don’t have a full understanding of who is at risk #lcsm
Brendon Stiles @BrendonStilesMD
T3. Survival data from limited resection trials not mature, but will be important as we consider other local treatments – SBRT or RFA #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @Smiles4Nana Clearly we have to identify risk factors other than just smoking. #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: .@findlungcancer had MANY great tweets about lung cancer screening presentations--search for her tweets #lcsm
Bob Steele @steele_bob
Given relative low cost for LD CT, why are we not pressing more for scans for young & mid adult ages! #lcsm
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical…
Dr. David Tom Cooke @DavidCookeMD
Some still think that the "jury is still out". The Jury is in, made their verdict, collected their per diem, and went back to work! #LCSM https://t.co/LKXeTCMugf
Faces of Lung Cancer @LungCancerFaces
Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. #lcsm
Brendon Stiles @BrendonStilesMD
T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm
Tiffini Joseph @Smiles4Nana
#433aday should be a big indicator #lcsm https://t.co/H6tWE4NnP7
Danielle Pardue @Actorielle
RT @DrHMahmud: It is helpful for saving lives, if we screen high-risk LC patients. #LCSM
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm
Enlightening Results @GraceCordovano
Just saying hello and wishing you all a wonderful #LCSM chat tonight. In between meetings. Will catch up later. 🌸
Diane @diianeee
THIS! RT @steele_bob: Given relative low cost for LD CT, why are we not pressing more for scans for young & mid adult ages! #lcsm
Eden Lake @EdenLake
RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @BrendonStilesMD I feel the screening should include those with family hx, not just older, heavy smokers. #lcsm
Danielle Pardue @Actorielle
RT @steele_bob: Given relative low cost for LD CT, why are we not pressing more for scans for young & mid adult ages! #lcsm
Brendon Stiles @BrendonStilesMD
Did I just say this out loud? #lcsm
IASLC @IASLC
RT @LungCancerFaces: T2: @IASLC is doing an outstanding job in giving patients the opportunity to go to #WCLC2017. I'm excited for Toronto…
Danielle Pardue @Actorielle
RT @DavidCookeMD: Some still think that the "jury is still out". The Jury is in, made their verdict, collected their per diem, and w…
Janet Freeman-Daily @JFreemanDaily
T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lungcancer #lcsm
Ian Pereira @IanJPereira
#RadOnc https://t.co/tpAFb4JAlc
Danielle Pardue @Actorielle
RT @LungCancerFaces: Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher.…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T3: #WCLC2017 had some great presentations on how to decide whether a lung nodule required action #lcsm
Brendon Stiles @BrendonStilesMD
T3. Role of SBRT in operable patients remains undefined but solid arguments can be made on both sides. #lcsm
Dr. David Tom Cooke @DavidCookeMD
What was the abstract number? #LCSM https://t.co/AIpJKuoTH7
Danielle Pardue @Actorielle
RT @JFreemanDaily: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lu
Shankar Siva @_ShankarSiva
T3 - interestingly my resp. physician colleagues aren’t excited about screening in Oz - we are unlikely to do this anytime soon 🇦🇺 #LCSM
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm
Happiehippiehomie @ohsnapkipd
RT @EdenLake: Congrats @Actorielle #lcsm
Geri Massa @GeriGerim13
@LungCancerFaces #LCSM , what if over a certain age or if ANY Cancer in family, do a low dose Scan 1X a year. I don’t know what long term eff.on scans
Brendon Stiles @BrendonStilesMD
@JFreemanDaily This key. Be thoughtful and do no harm. #lcsm
Eden Lake @EdenLake
@BrendonStilesMD to a large extent, I think it is a doctor issue. Even with a chest xray and lung spot, had hard time getting scoped #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Also strong focus on quality assurance and training for CT screening. #lcsm
#LCSM Chat @lcsmchat
RT @DavidCookeMD: T3 I think it is a provider (doctor) issue. #LCSM https://t.co/47V22OEmaE
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Great updates on limited resection trials. Extremely low mortality (0% in Japanese trial). Will be new surgical…
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @DavidCookeMD T3: agreed. General practitioners especially don’t have a full understanding of who is at risk #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @Smiles4Nana Clearly we have to identify risk factors other than just smoking. #lcsm
Danielle Pardue @Actorielle
RT @GERI1365: @LungCancerFaces #LCSM , what if over a certain age or if ANY Cancer in family, do a low dose Scan 1X a year. I don…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: .@findlungcancer had MANY great tweets about lung cancer screening presentations--search for her tweets #lcsm
#LCSM Chat @lcsmchat
RT @DrHMahmud: It is helpful for saving lives, if we screen high-risk LC patients. #LCSM
Janet Freeman-Daily @JFreemanDaily
@steele_bob Increasing age increases risk--younger people are not yet high enough risk to justify screening (so they say) #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Survival data from limited resection trials not mature, but will be important as we consider other local treatmen…
robin boquet @roblnboquet
RT @GERI1365: I would love to be able to attend webinars live, or have library #LCSM
Brendon Stiles @BrendonStilesMD
T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn't so Innocent #lcsm
Tiffini Joseph @Smiles4Nana
#stigma! #lcsm https://t.co/upwQjAUIxP
Danielle Pardue @Actorielle
RT @JFreemanDaily: @steele_bob Increasing age increases risk--younger people are not yet high enough risk to justify screening (so they say…
#LCSM Chat @lcsmchat
RT @DavidCookeMD: Some still think that the "jury is still out". The Jury is in, made their verdict, collected their per diem, and w…
Janet Freeman-Daily @JFreemanDaily
@DavidCookeMD Would have to look for the tweet and do some sleuthing #lcsm
Andrea Borondy Kitts @findlungcancer
just popping in for a minute -- it's both; but obviously need docs to recommend similar to other types cancer screening #lcsm https://t.co/kQJn2e69sJ
#LCSM Chat @lcsmchat
RT @LungCancerFaces: Nihilism among patients and PCPs is an issue MT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher.…
Brendon Stiles @BrendonStilesMD
This is an important concept. Don't ignore or delay w/u of nodules in never smokers. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Continue to see strong data from SBRT #radonc for treatment of early lung cancer. #lcsm
#LCSM Chat @lcsmchat
RT @Smiles4Nana: #433aday should be a big indicator #lcsm https://t.co/H6tWE4NnP7
Lung Cancer Sux @LungCancerSux
RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn'…
Clive Peedell @cpeedell
@BrendonStilesMD T3 Need to see successful trial recruitment for a SABR versus Surgery trial. Will VALOR & STABLEMATES succeed where others failed? #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lu
matthew allen @matthewalleno6
RT @Smiles4Nana: @BrendonStilesMD T2: what better attendees than patients to advocate for themselves and their desired aspects of care #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Role of SBRT in operable patients remains undefined but solid arguments can be made on both sides. #lcsm
Ian Pereira @IanJPereira
@JFreemanDaily Interesting. Haven't seen much #lungcancer data from China. Unsurprising given the #airquality situation. Wonder what pathology tells #lcsm
#LCSM Chat @lcsmchat
RT @DavidCookeMD: What was the abstract number? #LCSM https://t.co/AIpJKuoTH7
#LCSM Chat @lcsmchat
RT @_ShankarSiva: T3 - interestingly my resp. physician colleagues aren’t excited about screening in Oz - we are unlikely to do this anytim…
Ian Pereira @IanJPereira
RT @JFreemanDaily: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lu
BUY FOLLO₩ERS ,abo @krapfnadia
RT @JFreemanDaily: T3: I think I saw presentations about a screening study in China that included never smokers--increased diagnosis of #lu
Brendon Stiles @BrendonStilesMD
@cpeedell Hopefully a resounding "yes". #lcsm
Ian Pereira @IanJPereira
#RadOnc https://t.co/prYryQZFoZ
eqbal jamshed @ejamshed
RT @CUCancerCenter: Study finds breast cancer driver in 3 percent of lung cancers #LCSM #BCSM https://t.co/eBTK8y8Npf https://t.co/oLLiu2du…
Andrea Borondy Kitts @findlungcancer
Agree - biomarkers - blood/plasma; breath; validated population risk prediction model inc 2nd hand smoke, pollution, genetics #lcsm https://t.co/tP9Q3vkJmT
Geri Massa @GeriGerim13
The Cancer center here offered a $99 low dose CT scan takes about 10 min. Had to qualify smoker, age, cancer family history #lcsm
Janet Freeman-Daily @JFreemanDaily
T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https://t.co/D2BtaDTYBK
Ian Pereira @IanJPereira
@_ShankarSiva What do you think may be driving less screening down under? #lcsm T3
Brendon Stiles @BrendonStilesMD
T3. And of course always love focus on quality of surgery and pathologic staging and evaluation. #lcsm
#LCSM Chat @lcsmchat
RT @GERI1365: @LungCancerFaces #LCSM , what if over a certain age or if ANY Cancer in family, do a low dose Scan 1X a year. I don…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @JFreemanDaily This key. Be thoughtful and do no harm. #lcsm
Clive Peedell @cpeedell
@BrendonStilesMD T1 Surgeons staying in the game with new techniques. Less morbidity and mortality. Exciting future for beam versus blade! #lcsm
#LCSM Chat @lcsmchat
RT @EdenLake: @BrendonStilesMD to a large extent, I think it is a doctor issue. Even with a chest xray and lung spot, had hard time getting…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @steele_bob Increasing age increases risk--younger people are not yet high enough risk to justify screening (so they say…
Lung Cancer Sux @LungCancerSux
RT @JFreemanDaily: T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https:…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn'…
#LCSM Chat @lcsmchat
RT @Smiles4Nana: #stigma! #lcsm https://t.co/upwQjAUIxP
#LCSM Chat @lcsmchat
RT @findlungcancer: just popping in for a minute -- it's both; but obviously need docs to recommend similar to other types cancer scree…
Siera Harris @sieraharris9271
RT @BrendonStilesMD: T3. Not clear to me why screening rate isn't higher. Lack of knowledge? Patients? Doctors? #lcsm
Brendon Stiles @BrendonStilesMD
Going to shift to medical oncology and advanced disease soon. Lots of action. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: This is an important concept. Don't ignore or delay w/u of nodules in never smokers. #lcsm
#LCSM Chat @lcsmchat
RT @cpeedell: @BrendonStilesMD T3 Need to see successful trial recruitment for a SABR versus Surgery trial. Will VALOR & STABLEMA…
Dr. David Tom Cooke @DavidCookeMD
Should be free by medicare and private insurance if fit the recommend risk factors. #LungCancerScreening #LCSM https://t.co/5rcrYHClF3
#LCSM Chat @lcsmchat
RT @IJohnPereira: @JFreemanDaily Interesting. Haven't seen much #lungcancer data from China. Unsurprising given the #airquality situa…
Shankar Siva @_ShankarSiva
T3 - super important studies. POSTLIV also running in China, SABRTOOTH in UK closed I hear? #LCSM @cpeedell https://t.co/qbKhnTqNNg
#LCSM Chat @lcsmchat
RT @findlungcancer: Agree - biomarkers - blood/plasma; breath; validated population risk prediction model inc 2nd hand smoke, pollution…
Janet Freeman-Daily @JFreemanDaily
T3: #lungcancer screening in China @IASLC #WCLC2017 #lcsm https://t.co/EccZRS5i0y
Andrea Borondy Kitts @findlungcancer
maybe depending on number relatives diagnosed & other risk factors e.g. 2nd hand smoke, pollution, radon #lcsm https://t.co/2dKSSA7cXv
Brendon Stiles @BrendonStilesMD
@cpeedell "Beam vs. blade" sounds nice. I see video trailers... #lcsm
Geri Massa @GeriGerim13
You would 🤔 think the money potential savings by catching early would outweigh finding at Stg 3 & 4 #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https:…
Brendon Stiles @BrendonStilesMD
T4: What is new in advanced disease and medical oncology? #lcsm
eqbal jamshed @ejamshed
RT @findlungcancer: Positive Hospital Marketing Campaigns Have A Painful Downside : Shots - Health News : NPR #bcsm #lcsm https://t.co/wub…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T3. And of course always love focus on quality of surgery and pathologic staging and evaluation. #lcsm
#LCSM Chat @lcsmchat
RT @cpeedell: @BrendonStilesMD T1 Surgeons staying in the game with new techniques. Less morbidity and mortality. Exciting future…
Anita Figueras @scifiknitter
RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn'…
#LCSM Chat @lcsmchat
RT @DavidCookeMD: Should be free by medicare and private insurance if fit the recommend risk factors. #LungCancerScreening #LCSM https://t.…
Danielle Pardue @Actorielle
RT @GERI1365: You would 🤔 think the money potential savings by catching early would outweigh finding at Stg 3 & 4 #lcsm
Danielle Pardue @Actorielle
RT @findlungcancer: maybe depending on number relatives diagnosed & other risk factors e.g. 2nd hand smoke, pollution, radon #lcsm https://…
Danielle Pardue @Actorielle
RT @JFreemanDaily: T3: #lungcancer screening in China @IASLC #WCLC2017 #lcsm https://t.co/EccZRS5i0y
#LCSM Chat @lcsmchat
RT @_ShankarSiva: T3 - super important studies. POSTLIV also running in China, SABRTOOTH in UK closed I hear? #LCSM @cpeedell https://t.co/…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T3: #lungcancer screening in China @IASLC #WCLC2017 #lcsm https://t.co/EccZRS5i0y
Brendon Stiles @BrendonStilesMD
T4. Targeted therapy and immunotherapy bonanza! #lcsm
#LCSM Chat @lcsmchat
RT @findlungcancer: maybe depending on number relatives diagnosed & other risk factors e.g. 2nd hand smoke, pollution, radon #lcsm https://…
Danielle Pardue @Actorielle
RT @DavidCookeMD: Should be free by medicare and private insurance if fit the recommend risk factors. #LungCancerScreening #LCSM https://t.…
Tiffini Joseph @Smiles4Nana
RT @GERI1365: You would 🤔 think the money potential savings by catching early would outweigh finding at Stg 3 & 4 #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: T3: Soon to be published EU statement on #lungcancer screening in Europe #WCLC2017 #LCSM (H/T to @findlungcancer) https:…
Tiffini Joseph @Smiles4Nana
@findlungcancer Exactly #lcsm
Faces of Lung Cancer @LungCancerFaces
@BrendonStilesMD @cpeedell And a voice over done by a man with a deep, gravelly voice... #lcsm
Shankar Siva @_ShankarSiva
@BrendonStilesMD T4 - FLAURA data for osimertinib pretty exciting for advanced eGFR NSCLC #LCSM
Janet Freeman-Daily @JFreemanDaily
@findlungcancer! Welcome back! #lcsm
Danielle Pardue @Actorielle
RT @Smiles4Nana: #stigma! #lcsm https://t.co/upwQjAUIxP
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4: What is new in advanced disease and medical oncology? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Targeted therapy and immunotherapy bonanza! #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn'…
#LCSM Chat @lcsmchat
RT @_ShankarSiva: @BrendonStilesMD T4 - FLAURA data for osimertinib pretty exciting for advanced eGFR NSCLC #LCSM
Shankar Siva @_ShankarSiva
RT @_ShankarSiva: T1 - a lot of excitement about #ImmunoOnc at #WCLC2017 - do we worry about rising costs and choosing wisely in lung cance…
Brendon Stiles @BrendonStilesMD
T4. Emphasis on guidelines for molecular testing…from @RielyMD #lcsm https://t.co/RFSXDEjqwz
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T4: What is new in advanced disease and medical oncology? #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T4. Targeted therapy and immunotherapy bonanza! #lcsm
Eden Lake @EdenLake
T4 more immunotherapy exploration and focus on way to make it financially accessable for all viable patients please! @BrendonStilesMD #lcsm
Brendon Stiles @BrendonStilesMD
@_ShankarSiva Yes..incredible. #LCSM
Danielle Pardue @Actorielle
RT @_ShankarSiva: @BrendonStilesMD T4 - FLAURA data for osimertinib pretty exciting for advanced eGFR NSCLC #LCSM
Bob Steele @steele_bob
Limiting scans to high risk factor profiles clearly isn't enough. We wait way too late! #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T4. Emphasis on guidelines for molecular testing…from @RielyMD #lcsm https://t.co/RFSXDEjqwz
Danielle Pardue @Actorielle
RT @EdenLake: T4 more immunotherapy exploration and focus on way to make it financially accessable for all viable patients please! @Brendon
Shankar Siva @_ShankarSiva
T4 - ok on right topic now, thoughts for below? #lcsm https://t.co/c5LUZyPPJ3
Eden Lake @EdenLake
T4 we need more opportunity for early stage patients to access immunotherapy trials too... #lcsm
Danielle Pardue @Actorielle
RT @steele_bob: Limiting scans to high risk factor profiles clearly isn't enough. We wait way too late! #lcsm
Bob Steele @steele_bob
RT @EdenLake: T4 we need more opportunity for early stage patients to access immunotherapy trials too... #lcsm
Brendon Stiles @BrendonStilesMD
T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm https://t.co/xc2iHM6HOe
Eden Lake @EdenLake
RT @steele_bob: Limiting scans to high risk factor profiles clearly isn't enough. We wait way too late! #lcsm
Tiffini Joseph @Smiles4Nana
@IntrovertinNC @LungCancerFaces @BrendonStilesMD @cpeedell Of course! #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Emphasis on guidelines for molecular testing…from @RielyMD #lcsm https://t.co/RFSXDEjqwz
Janet Freeman-Daily @JFreemanDaily
T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr
#LCSM Chat @lcsmchat
RT @EdenLake: T4 more immunotherapy exploration and focus on way to make it financially accessable for all viable patients please! @Brendon
Tiffini Joseph @Smiles4Nana
RT @steele_bob: Limiting scans to high risk factor profiles clearly isn't enough. We wait way too late! #lcsm
Clive Peedell @cpeedell
@BrendonStilesMD Robot Wars too! Da Vinci versus Cyberknife #lcsm
Danielle Pardue @Actorielle
RT @EdenLake: T4 we need more opportunity for early stage patients to access immunotherapy trials too... #lcsm
#LCSM Chat @lcsmchat
RT @_ShankarSiva: T4 - ok on right topic now, thoughts for below? #lcsm https://t.co/c5LUZyPPJ3
#LCSM Chat @lcsmchat
RT @EdenLake: T4 we need more opportunity for early stage patients to access immunotherapy trials too... #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm ht…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm ht…
Brendon Stiles @BrendonStilesMD
@_ShankarSiva Cost is definitely running crazy. I agree with idea of value based approval and PFS/OS endpoints. #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr
Brendon Stiles @BrendonStilesMD
@cpeedell I want movie rights. #lcsm
Brendon Stiles @BrendonStilesMD
T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm
Andrea Borondy Kitts @findlungcancer
Liverpool #lungcancer screening project patient engagement via GP was key factor @DavidCookeMD #lcsm https://t.co/qYgINR6gGK
Tiffini Joseph @Smiles4Nana
T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM
Matthew Katz, MD @subatomicdoc
RT @BrendonStilesMD: @JFreemanDaily This key. Be thoughtful and do no harm. #lcsm
Anita Figueras @scifiknitter
RT @BrendonStilesMD: T4. Continue to see interesting data about EGFR TKI resistance and sequencing of therapy. From @DrRiyazShah #lcsm ht…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @_ShankarSiva Cost is definitely running crazy. I agree with idea of value based approval and PFS/OS endpoints. #lcsm
Acord@dinho @acordadinho
RT @findlungcancer: Positive Hospital Marketing Campaigns Have A Painful Downside : Shots - Health News : NPR #bcsm #lcsm https://t.co/wub…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm
#LCSM Chat @lcsmchat
RT @findlungcancer: Liverpool #lungcancer screening project patient engagement via GP was key factor @DavidCookeMD #lcsm https://t.co/qYgIN…
Hossen Mahmud, MD @DrHMahmudMD
For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #LCSM
#LCSM Chat @lcsmchat
RT @Smiles4Nana: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM
Brendon Stiles @BrendonStilesMD
@Smiles4Nana Great point. Have to make sure it is happening everywhere, because there are great treatments out there. #lcsm
Eden Lake @EdenLake
RT @Smiles4Nana: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM
Denise Cutlip @dennycee
Exactly https://t.co/tzv7G6OZG2
Danielle Pardue @Actorielle
RT @Smiles4Nana: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM
Shankar Siva @_ShankarSiva
T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV NSCLV #LCSM @wallyjc https://t.co/uGDGsF7CyF
Danielle Pardue @Actorielle
RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agent…
Janet Freeman-Daily @JFreemanDaily
@Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situation. #lcsm
Anita Figueras @scifiknitter
RT @BrendonStilesMD: T4. Liquid biopsies are hot! Need to balance convenience with decreased sensitivity and discordance w/ tissue. #lcsm
Andrea Borondy Kitts @findlungcancer
Ads Liverpool #lungcancer screening project @DavidCookeMD #lcsm https://t.co/8YVX7NbY3F
Lung Cancer Sux @LungCancerSux
RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agent…
Tiffini Joseph @Smiles4Nana
@BrendonStilesMD Those receiving tx by specialists. Unfortunately, so many are still being treated in the community #lcsm
Hossen Mahmud, MD @DrHMahmudMD
For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agents. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @Smiles4Nana Great point. Have to make sure it is happening everywhere, because there are great treatments out there.…
Danielle Pardue @Actorielle
RT @_ShankarSiva: T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV N…
#LCSM Chat @lcsmchat
RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agent…
Brendon Stiles @BrendonStilesMD
T4. Interesting data about mutation burden and small cell. From @peters_solange. When will see routine use of IO for small cell? #lcsm https://t.co/AaKGTjGkHt
Lung Cancer Sux @LungCancerSux
RT @JFreemanDaily: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situa…
Danielle Pardue @Actorielle
RT @JFreemanDaily: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situa…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @Smiles4Nana Great point. Have to make sure it is happening everywhere, because there are great treatments out there.…
#LCSM Chat @lcsmchat
RT @_ShankarSiva: T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV N…
Bob Steele @steele_bob
RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agent…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situa…
Tiffini Joseph @Smiles4Nana
RT @JFreemanDaily: @Smiles4Nana T4: Not enough patients getting reflex genomic testing, but liquid biopsies may soon help improve the situa…
#LCSM Chat @lcsmchat
RT @findlungcancer: Ads Liverpool #lungcancer screening project @DavidCookeMD #lcsm https://t.co/8YVX7NbY3F
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @BrendonStilesMD Those receiving tx by specialists. Unfortunately, so many are still being treated in the community #lcsm
Nay @ChancesR3
@DrHMahmud @LungCancerSux Yes - this is such a game-changer. #lcsm
#LCSM Chat @lcsmchat
RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agent…
Andrea Borondy Kitts @findlungcancer
Many smokers in Liverpool: smoking everywhere @DavidCookeMD #lcsm https://t.co/Ug1uxm6aDW
Clive Peedell @cpeedell
@_ShankarSiva T4 Also big issue around testing costs for targeted therapies. Lots of new drugs with activity for uncommon/rare mutation +ve tumours #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Interesting data about mutation burden and small cell. From @peters_solange. When will see routine use of IO…
Danielle Pardue @Actorielle
RT @DrHMahmud: For metastatic LCs we still have to find a better way to control and manage the disease with more targeted therapeutic agent…
Janet Freeman-Daily @JFreemanDaily
T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X
Brendon Stiles @BrendonStilesMD
@JFreemanDaily @Smiles4Nana I think this is going to definitely be true. #lcsm
Janet Freeman-Daily @JFreemanDaily
T4: nivolumab efficacy enhanced in SCLC with high Tumor Mutation Burden (TMB) w/ or w/o ipilimumab #WCLC2017 #LCSM https://t.co/efZGG8ybsc
Bob Steele @steele_bob
RT @JFreemanDaily: T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X
Andrea Borondy Kitts @findlungcancer
The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U
Clive Peedell @cpeedell
@BrendonStilesMD @_ShankarSiva T4 We really need some high quality health economic studies #Lcsm
Brendon Stiles @BrendonStilesMD
T4. Agree_Interesting things happening for ROS1: standardtesting, entrectinib treatment. From @MSPneu #lcsm https://t.co/q8BGjwMp9w
Tiffini Joseph @Smiles4Nana
@BrendonStilesMD @JFreemanDaily This is why education and advocacy is such an integral piece of progress #lcsm
Danielle Pardue @Actorielle
RT @cpeedell: @_ShankarSiva T4 Also big issue around testing costs for targeted therapies. Lots of new drugs with activity for un…
Danielle Pardue @Actorielle
RT @JFreemanDaily: T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X
Dr. David Tom Cooke @DavidCookeMD
One of the roles of #LCSM movement. "Education and Advocacy". https://t.co/tPkqhRkknE
Brendon Stiles @BrendonStilesMD
@cpeedell @_ShankarSiva Across the board. Not sustainable at current rate. But access is key. #lcsm
#LCSM Chat @lcsmchat
RT @cpeedell: @_ShankarSiva T4 Also big issue around testing costs for targeted therapies. Lots of new drugs with activity for un…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T4: Entrectinib is very promising drug for #ROS1 patients, and treats brain mets. #WCLC2017 #LCSM https://t.co/28rQz19A4X
Enlightening Results @GraceCordovano
@JFreemanDaily @Smiles4Nana No. Not universally recommended. Not fully reimbursed. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T4: nivolumab efficacy enhanced in SCLC with high Tumor Mutation Burden (TMB) w/ or w/o ipilimumab #WCLC2017 #LCSM https…
Danielle Pardue @Actorielle
RT @findlungcancer: The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U
#LCSM Chat @lcsmchat
RT @findlungcancer: The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U
#LCSM Chat @lcsmchat
RT @cpeedell: @BrendonStilesMD @_ShankarSiva T4 We really need some high quality health economic studies #Lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Agree_Interesting things happening for ROS1: standardtesting, entrectinib treatment. From @MSPneu #lcsm https:/…
Tiffini Joseph @Smiles4Nana
@DavidCookeMD So true! #lcsm proud to be a part of it!
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @BrendonStilesMD @JFreemanDaily This is why education and advocacy is such an integral piece of progress #lcsm
Danielle Pardue @Actorielle
RT @DavidCookeMD: One of the roles of #LCSM movement. "Education and Advocacy". https://t.co/tPkqhRkknE
#LCSM Chat @lcsmchat
RT @DavidCookeMD: One of the roles of #LCSM movement. "Education and Advocacy". https://t.co/tPkqhRkknE
Dr. David Tom Cooke @DavidCookeMD
RT @Smiles4Nana: @DavidCookeMD So true! #lcsm proud to be a part of it!
Brendon Stiles @BrendonStilesMD
T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm
Clive Peedell @cpeedell
@BrendonStilesMD Too late, Brendon! #lcsm https://t.co/FDzaEiS0E7
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @DavidCookeMD So true! #lcsm proud to be a part of it!
Eden Lake @EdenLake
RT @cpeedell: @BrendonStilesMD @_ShankarSiva T4 We really need some high quality health economic studies #Lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm
Treatment for Cancer @cancer_tm
RT @JFreemanDaily: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm
Nay @ChancesR3
@EdenLake @steele_bob Even late stage. My husband being eval for 5th line treatment - duvalumab and AZD6738. Immunotherapy that might work with EGFR. #lcsm #hope
Tiffini Joseph @Smiles4Nana
@GraceCordovano @JFreemanDaily I feel like saving lives should always be universally recommended #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm
Sakshi Saini @Sakshi1185
RT @Tony_Calles: Bye bye chemo👋 #WCLC2017 Median overall survival 30 months 1st line Pembrolizumab in PD-L1+ >=50% NSCLC #lcsm https://t.co…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm
Bob Steele @steele_bob
RT @Smiles4Nana: @DavidCookeMD So true! #lcsm proud to be a part of it!
Hossen Mahmud, MD @DrHMahmudMD
RT @JFreemanDaily: T1: #WCLC2017 is a great opportunity for networking among #lungcancer researchers and clinicians #lcsm
giulia albergo @giuliaa__lovee
RT @EdenLake: T4 we need more opportunity for early stage patients to access immunotherapy trials too... #lcsm
Eden Lake @EdenLake
@ChancesR3 @steele_bob YES... praying for good results for him #lcsm
Danielle Pardue @Actorielle
RT @Smiles4Nana: @GraceCordovano @JFreemanDaily I feel like saving lives should always be universally recommended #lcsm
Faces of Lung Cancer @LungCancerFaces
@cpeedell @BrendonStilesMD Fight for your life sounds about right... #lcsm
Britnie Lynn @brltkhaos
RT @Smiles4Nana: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM
Brendon Stiles @BrendonStilesMD
@_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different agenda. #lcsm
#LCSM Chat @lcsmchat
RT @ChancesR3: @EdenLake @steele_bob Even late stage. My husband being eval for 5th line treatment - duvalumab and AZD6738. Immuno…
Danielle Pardue @Actorielle
RT @LungCancerFaces: @cpeedell @BrendonStilesMD Fight for your life sounds about right... #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different…
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @GraceCordovano @JFreemanDaily I feel like saving lives should always be universally recommended #lcsm
Nay @ChancesR3
@EdenLake @steele_bob Thank you! #lcsm
Brendon Stiles @BrendonStilesMD
@Smiles4Nana @GraceCordovano @JFreemanDaily I agree and I will put this forward a universal proposal for all societies! #lcsm
Tiffini Joseph @Smiles4Nana
@IntrovertinNC @GraceCordovano @JFreemanDaily Common sense...not so common, sadly #lcsm
Janet Freeman-Daily @JFreemanDaily
@GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcancer patients. #lcsm
Tiffini Joseph @Smiles4Nana
RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcan
Danielle Pardue @Actorielle
RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcan
Brendon Stiles @BrendonStilesMD
Great science. Great trials. Great conversation. Coming to T5. #lcsm
Danielle Pardue @Actorielle
RT @Smiles4Nana: @IntrovertinNC @GraceCordovano @JFreemanDaily Common sense...not so common, sadly #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @Smiles4Nana @GraceCordovano @JFreemanDaily I agree and I will put this forward a universal proposal for all societies…
Christopher Donley @onehandedpotter
RT @JFreemanDaily: T4: Update on data for lorlatinib to treat ALK+ and ROS1+ NSCLC #WCLC2017 #LCSM https://t.co/JuilMOafVr
Shankar Siva @_ShankarSiva
@cpeedell @BrendonStilesMD T4 - yes the UK are usually leaders in pragmatic trials no one else can do #lcsm
Brendon Stiles @BrendonStilesMD
T5: Were there any exciting new areas of translational research that show particular promise for patients with lung cancer? #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different…
Tiffini Joseph @Smiles4Nana
RT @BrendonStilesMD: Great science. Great trials. Great conversation. Coming to T5. #lcsm
Bob Steele @steele_bob
RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcan
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5: Were there any exciting new areas of translational research that show particular promise for patients with lung c…
#LCSM Chat @lcsmchat
RT @_ShankarSiva: @cpeedell @BrendonStilesMD T4 - yes the UK are usually leaders in pragmatic trials no one else can do #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5: Were there any exciting new areas of translational research that show particular promise for patients with lung c…
Brendon Stiles @BrendonStilesMD
T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important. #lcsm
ShereeseM, MS/MBA @ShereesePubHlth
RT @findlungcancer: The results by the numbers Liverpool #lungcancer screening project #lcsm https://t.co/wysFTMlH1U
Janet Freeman-Daily @JFreemanDaily
T5: Dr. Julie Brahmer from @HopkinsMedicine & top experts discussed possible new #biomarkers for #lungcancer #Immunotherapy #LCSM #WCLC2017 https://t.co/mlzo9IqaO0
Brendon Stiles @BrendonStilesMD
T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different cancers. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important…
Eden Lake @EdenLake
RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm
Hossen Mahmud, MD @DrHMahmudMD
@BrendonStilesMD That was interesting to hear many inputs from many people. #LCSM https://t.co/Rrmp6hsYwV
Mr.Sixtyniner™ @lilltwit86
RT @Smiles4Nana: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM
Tiffini Joseph @Smiles4Nana
RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important…
Eden Lake @EdenLake
RT @Smiles4Nana: @GraceCordovano @JFreemanDaily I feel like saving lives should always be universally recommended #lcsm
Lung Cancer Sux @LungCancerSux
RT @BrendonStilesMD: T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different c…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T5: Dr. Julie Brahmer from @HopkinsMedicine & top experts discussed possible new #biomarkers for #lungcancer
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different c…
Brendon Stiles @BrendonStilesMD
T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed to lung cancer? #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: T5: Dr. Julie Brahmer from @HopkinsMedicine & top experts discussed possible new #biomarkers for #lungcancer
#LCSM Chat @lcsmchat
RT @DrHMahmud: @BrendonStilesMD That was interesting to hear many inputs from many people. #LCSM https://t.co/Rrmp6hsYwV
Nay @ChancesR3
RT @BrendonStilesMD: T5. Continued investigation into tumor heterogeneity – how different parts of tumors are distinct – is quite important…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. Also love molecular characterization of different adeno subtypes (ID 9412). Adenocarcinomas are quite different c…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed…
Brendon Stiles @BrendonStilesMD
T5. Interesting to see possibility of discordant PD-L1 results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm
Vincent Chavanon @vchavan0n
RT @EdenLake: T4 more immunotherapy exploration and focus on way to make it financially accessable for all viable patients please! @Brendon
Eden Lake @EdenLake
T4 Everyone who has appropriate markers to offer potential benefit, regardless of stage #lcsm @BrendonStilesMD
Nay @ChancesR3
RT @BrendonStilesMD: T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed…
Jim Saladin @jsinkc439
RT @BrendonStilesMD: T4. Still bouncing around - who should get frontline immunotherapy for NSCLC? #lcsm
Deb Smith 🍀 @debsmithbeach
RT @_ShankarSiva: T3 & T4 aLots to be excited about with improvements from trials over the years in stage III (yellow) and stage IV N…
Tiffini Joseph @Smiles4Nana
@BrendonStilesMD I always wonder this. Why one smoker gets LC yet another doesn’t. Why does is run rampant through some families, yet some are isolated #lcsm
Brendon Stiles @BrendonStilesMD
T5. Interesting to see possibility of discordant PD-L1 testing results from same patient (22.2% in ID 10357). ? value of repeat test. #lcsm
Janet Freeman-Daily @JFreemanDaily
@EdenLake Not so fast ... why give stage 1 patients targeted therapies (which can't cure) when they can have curative treatment? #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 results from same patient (22.2% in ID 10357). ? value of repe…
Brendon Stiles @BrendonStilesMD
T5. Continued work on tumor mutation burden as predictor of immune response (ID 11063) #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 testing results from same patient (22.2% in ID 10357). ? value…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. In ref to screening: Work on germline mutations from Ohio State, ID8670. Are some patients genetically predisposed…
Andrea Borondy Kitts @findlungcancer
implementation waits for NELSON trail results; if imp mortality similar NLST will go ahead; if no impvmt will not; results in 1 year #lcsm https://t.co/ThBIzoWzXJ
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 results from same patient (22.2% in ID 10357). ? value of repe…
#LCSM Chat @lcsmchat
RT @EdenLake: T4 Everyone who has appropriate markers to offer potential benefit, regardless of stage #lcsm @BrendonStilesMD
#LCSM Chat @lcsmchat
RT @Smiles4Nana: @BrendonStilesMD I always wonder this. Why one smoker gets LC yet another doesn’t. Why does is run rampant through…
Brendon Stiles @BrendonStilesMD
@Smiles4Nana Has to be something genetic there somewhere. Just haven't found it yet. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Interesting to see possibility of discordant PD-L1 testing results from same patient (22.2% in ID 10357). ? value…
Ian Pereira @IanJPereira
RT @JFreemanDaily: T3: #WCLC2017 had some great presentations on how to decide whether a lung nodule required action #lcsm
Ian Pereira @IanJPereira
RT @BrendonStilesMD: @JFreemanDaily This key. Be thoughtful and do no harm. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @EdenLake Not so fast ... why give stage 1 patients targeted therapies (which can't cure) when they can have curative tr…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. Continued work on tumor mutation burden as predictor of immune response (ID 11063) #lcsm
#LCSM Chat @lcsmchat
RT @findlungcancer: implementation waits for NELSON trail results; if imp mortality similar NLST will go ahead; if no impvmt will not;…
Ian Pereira @IanJPereira
RT @BrendonStilesMD: T3. Reminder that lung cancer in never smokers not an indolent disease: P1.05-022d - Lung Cancer in the Innocent Isn'…
Janet Freeman-Daily @JFreemanDaily
T5: Nice to see analysis of Patient Reported Outcomes from a big trial; hope to see more of this in clinical trials #lcsm
Brendon Stiles @BrendonStilesMD
T5. More work on circulating free DNA as a biomarker and as a measure of response/recurrence. Will play increasing role. #lcsm
Eden Lake @EdenLake
Thats assuming 1) chemo/radiation is curative in all cases 2) that other health considerations dont make it prohibitive @JFreemanDaily #lcsm
Shankar Siva @_ShankarSiva
T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with a survival benefit #lcsm https://t.co/pASby1iwQD
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. Continued work on tumor mutation burden as predictor of immune response (ID 11063) #lcsm
Danielle Pardue @Actorielle
RT @findlungcancer: implementation waits for NELSON trail results; if imp mortality similar NLST will go ahead; if no impvmt will not;…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: @Smiles4Nana Has to be something genetic there somewhere. Just haven't found it yet. #lcsm
Danielle Pardue @Actorielle
RT @JFreemanDaily: T5: Nice to see analysis of Patient Reported Outcomes from a big trial; hope to see more of this in clinical trials #lcsm
Tiffini Joseph @Smiles4Nana
@BrendonStilesMD Even more reason LC needs a bigger piece of the research pie #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: T5. More work on circulating free DNA as a biomarker and as a measure of response/recurrence. Will play increasing ro…
Ian Pereira @IanJPereira
#RadOnc https://t.co/Op5pWw2Atm
Clive Peedell @cpeedell
T4 1.50am in UK! My tea's gone cold. Off to bed. Goodnight to all on #LCSM. Thanks to @BrendonStilesMD for an excellent job as moderator
#LCSM Chat @lcsmchat
RT @JFreemanDaily: T5: Nice to see analysis of Patient Reported Outcomes from a big trial; hope to see more of this in clinical trials #lcsm
Tiffini Joseph @Smiles4Nana
RT @_ShankarSiva: T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: T5. More work on circulating free DNA as a biomarker and as a measure of response/recurrence. Will play increasing ro…
Marita Lesch @MaritaLesch1
RT @OncologyTimes: NSCLC Survival Rates Higher Among Patients Treated at Academic Centers #WCLC2017 https://t.co/VtFCAnWV1w…
Janet Freeman-Daily @JFreemanDaily
@EdenLake Stage 1 is typically treated with surgery, curative in 80%+ of cases. Better option than targeted therapy. #lcsm
Andrea Borondy Kitts @findlungcancer
@trvanes @JFreemanDaily Yes I talked to presenter & implementation decision is awaiting NELSON trial results, all data in 6 weeks ago; 1 year for results #lcsm
Brendon Stiles @BrendonStilesMD
Just about time to wrap up. Lively chat although I suspect many #wclc2017 peeps are still drowning in sake. Closing thoughts? #lcsm
Brendon Stiles @BrendonStilesMD
@cpeedell Impressive rally. Thanks for joining and for always insightful comments. #lcsm
Eden Lake @EdenLake
@JFreemanDaily Or that financial considerations make extended chemo, radiation, surgery impossible. #lcsm
Brendon Stiles @BrendonStilesMD
@Smiles4Nana Like....gigantic. #lcsm
Danielle Pardue @Actorielle
RT @_ShankarSiva: T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with…
Brendon Stiles @BrendonStilesMD
Link to meeting site: https://t.co/i2pm35lAtm #lcsm
Danielle Pardue @Actorielle
RT @Smiles4Nana: @BrendonStilesMD Even more reason LC needs a bigger piece of the research pie #lcsm
Brendon Stiles @BrendonStilesMD
Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm
Tiffini Joseph @Smiles4Nana
Great chat!! Thank you lcsm https://t.co/6sgoFg2Wjk
Bob Steele @steele_bob
RT @BrendonStilesMD: Link to meeting site: https://t.co/i2pm35lAtm #lcsm
#LCSM Chat @lcsmchat
RT @EdenLake: Thats assuming 1) chemo/radiation is curative in all cases 2) that other health considerations dont make it prohibitive @JFre
Annie Heckenberger @anniemal
@BrendonStilesMD @Smiles4Nana Based on my family history and nothing more, I have to say yes. #lcsm
#LCSM Chat @lcsmchat
RT @_ShankarSiva: T5 - re: great trials, have to mention CHISEL by my boss; first trial of technology in oncology (that I know) with…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: Link to meeting site: https://t.co/i2pm35lAtm #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm
Janet Freeman-Daily @JFreemanDaily
CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
#LCSM Chat @lcsmchat
RT @cpeedell: T4 1.50am in UK! My tea's gone cold. Off to bed. Goodnight to all on #LCSM. Thanks to @BrendonStilesMD for an excellent job a…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: @EdenLake Stage 1 is typically treated with surgery, curative in 80%+ of cases. Better option than targeted therapy. #lc
#LCSM Chat @lcsmchat
RT @findlungcancer: @trvanes @JFreemanDaily Yes I talked to presenter & implementation decision is awaiting NELSON trial results, all d…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Just about time to wrap up. Lively chat although I suspect many #wclc2017 peeps are still drowning in sake. Closing th…
Bob Steele @steele_bob
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
Brendon Stiles @BrendonStilesMD
For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wclc2017 #lcsm
Faces of Lung Cancer @LungCancerFaces
Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiXZv9w We need you #lcsm
Andrea Borondy Kitts @findlungcancer
CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for Toronto 2018 #LCSM
Brendon Stiles @BrendonStilesMD
Great chat. Thanks everyone for sharing your insight. Get ready for #LCAM starting in November. Let’s make some noise! #lcsm
Eden Lake @EdenLake
@JFreemanDaily Kidney disease heart complications from kidney disease, additional systemic illness, my insurance company folding all factored stage 2 #lcsm
Geri Massa @GeriGerim13
Thank Y’all for the chat, I have a lot to learn 😊 #lcsm
Bob Steele @steele_bob
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
Lung Cancer Sux @LungCancerSux
RT @BrendonStilesMD: Link to meeting site: https://t.co/i2pm35lAtm #lcsm
Brendon Stiles @BrendonStilesMD
RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for…
Britnie Lynn @brltkhaos
RT @EdenLake: T4 we need more opportunity for early stage patients to access immunotherapy trials too... #lcsm
Brendon Stiles @BrendonStilesMD
Hope everyone makes it! #lcsm https://t.co/PfMMxWM28z
Denise Cutlip @dennycee
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
Danielle Pardue @Actorielle
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wcl
Brendon Stiles @BrendonStilesMD
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
Danielle Pardue @Actorielle
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
A.pretty.girl @nenadomlnadora
RT @Smiles4Nana: T4: question is, are enough patients getting the necessary genetic testing for target therapies? #LCSM
Tiffini Joseph @Smiles4Nana
@anniemal @BrendonStilesMD https://t.co/PVYR2jzyj1-quit smoking 20 yrs b4 dx, same with maternal Uncle, maternal gma neversmoker. Can’t tell me it’s not genetic #lcsm
Danielle Pardue @Actorielle
RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for…
Ian Pereira @IanJPereira
RT @cpeedell: @BrendonStilesMD @_ShankarSiva T4 We really need some high quality health economic studies #Lcsm
Tiffini Joseph @Smiles4Nana
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
Eden Lake @EdenLake
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
Danielle Pardue @Actorielle
RT @BrendonStilesMD: Hope everyone makes it! #lcsm https://t.co/PfMMxWM28z
Ian Pereira @IanJPereira
RT @BrendonStilesMD: @_ShankarSiva @cpeedell Pharma needs to be engaged or they will be overrun by studies by people with a much different…
Eden Lake @EdenLake
RT @BrendonStilesMD: Great chat. Thanks everyone for sharing your insight. Get ready for #LCAM starting in November. Let’s make some noi…
Tiffini Joseph @Smiles4Nana
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
Danielle Pardue @Actorielle
Thank you so much, my friends! Wonderful hour as always! #lcsm
Andrea Borondy Kitts @findlungcancer
RT @BrendonStilesMD: Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Link to meeting site: https://t.co/i2pm35lAtm #lcsm
Bob Steele @steele_bob
Now I can take my Delsym & Codeine. Good night all. Look forward to seeing you again in 2 weeks. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Press highlights: https://t.co/LjsICl2Sn3 PD-L1, exercise, community awareness #lcsm
Brendon Stiles @BrendonStilesMD
Thanks everyone. Have a great night! Keep talking about #LungCancer. We are making a difference in real people's lives. #lcsm
#LCSM Chat @lcsmchat
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wcl
#LCSM Chat @lcsmchat
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
Janet Freeman-Daily @JFreemanDaily
Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC2017! #lcsm
#LCSM Chat @lcsmchat
RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Great chat. Thanks everyone for sharing your insight. Get ready for #LCAM starting in November. Let’s make some noi…
Bob Steele @steele_bob
RT @JFreemanDaily: Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC
Eden Lake @EdenLake
Thank you all for fellowship, support, comraderie and comiseration as always. You make it more bearable. #lcsm
Danielle Pardue @Actorielle
RT @BrendonStilesMD: Thanks everyone. Have a great night! Keep talking about #LungCancer. We are making a difference in real people's li…
Danielle Pardue @Actorielle
RT @JFreemanDaily: Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC
Janet Freeman-Daily @JFreemanDaily
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
#LCSM Chat @lcsmchat
RT @BrendonStilesMD: Thanks everyone. Have a great night! Keep talking about #LungCancer. We are making a difference in real people's li…
#LCSM Chat @lcsmchat
RT @JFreemanDaily: Thanks to @brendonstilesMD for finding great chat topic, moderating, and pulling together highlights so soon after #WCLC
Shankar Siva @_ShankarSiva
Thank you @BrendonStilesMD for moderating - it’s the first chat I’ve engaged with! Been fun, let’s get back to work on lungcancer #lcsm
Bob Steele @steele_bob
RT @EdenLake: Thank you all for fellowship, support, comraderie and comiseration as always. You make it more bearable. #lcsm
Ian Pereira @IanJPereira
@cpeedell @BrendonStilesMD @_ShankarSiva I wond and if Canada & other countries exert the same buyer power to keep prices in check. #lcsm #cdnpoli #onpoli T4 #pharmacare?
#CorbynWins @davies42g
RT @cpeedell: T4 1.50am in UK! My tea's gone cold. Off to bed. Goodnight to all on #LCSM. Thanks to @BrendonStilesMD for an excellent job a…
#LCSM Chat @lcsmchat
RT @EdenLake: Thank you all for fellowship, support, comraderie and comiseration as always. You make it more bearable. #lcsm
#LCSM Chat @lcsmchat
RT @_ShankarSiva: Thank you @BrendonStilesMD for moderating - it’s the first chat I’ve engaged with! Been fun, let’s get back to work on lu…
Ian Pereira @IanJPereira
RT @JFreemanDaily: @GraceCordovano @Smiles4Nana Much work necessary to make broad molecular testing affordable and covered for all #lungcan
Kimberly Buchmeier @kimbuchmeier
Come to DC @BrendonStilesMD ! https://t.co/gc8iYNGdY3
Savvy Co-op | #askpatients @savvy_coop
RT @GraceCordovano: Amazing how following that “something” connects u w/most incredible people along the way. #hcldr #bcsm #lcsm
Janet Freeman-Daily @JFreemanDaily
@EdenLake Sorry you had issues complicating treatment (kidney and heart conditions might also prevent treatment with targeted therapy) #LCSM
Ian Pereira @IanJPereira
#RadOnc https://t.co/uZWFCOgeAD
Treatment for Cancer @cancer_tm
RT @NCICancerStats: Death rates for #LungCancer have been falling on average 2.5% each year between 2005-2014. Learn more:…
Ian Pereira @IanJPereira
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
Ian Pereira @IanJPereira
RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wcl
Ian Pereira @IanJPereira
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
Ian Pereira @IanJPereira
RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for…
Dr. David Tom Cooke @DavidCookeMD
RT @findlungcancer: CT #WCLC2017 a great conference; many studies new treatments & comparison established treatments. I can hardly wait for…
Dr. David Tom Cooke @DavidCookeMD
RT @LungCancerFaces: Many thanks to our moderator @BrendonStilesMD. Please come to DC 11/2 for the Life & Breath Rally: https://t.co/LWTRiX…
Nay @ChancesR3
@EdenLake I'm sending you support Eden. Sorry we haven't connected much but you are in my thoughts. #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wcl
Dr. David Tom Cooke @DavidCookeMD
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
Nay @ChancesR3
RT @BrendonStilesMD: Link to meeting site: https://t.co/i2pm35lAtm #lcsm
Dr. David Tom Cooke @DavidCookeMD
RT @JFreemanDaily: @EdenLake Stage 1 is typically treated with surgery, curative in 80%+ of cases. Better option than targeted therapy. #lc
lashawn kardashian @obey__kardashia
RT @EdenLake: Thats assuming 1) chemo/radiation is curative in all cases 2) that other health considerations dont make it prohibitive @JFre
Dr. David Tom Cooke @DavidCookeMD
RT @OncologyTimes: NSCLC Survival Rates Higher Among Patients Treated at Academic Centers #WCLC2017 https://t.co/VtFCAnWV1w…
Let's Cure ALK+ Lung Cancer! @VirginiaMByrne
RT @BrendonStilesMD: For me, it is so important to engage patients/advocates in science and clinical trials. @iaslc does a great job. #wcl
Ian Pereira @IanJPereira
Thanks #lcsm for your insights. Looking forward to #wclc2018 & everything in between.
Let's Cure ALK+ Lung Cancer! @VirginiaMByrne
RT @Smiles4Nana: @BrendonStilesMD Even more reason LC needs a bigger piece of the research pie #lcsm
🇺🇸Ashley🇺🇸 @kymama16
RT @JFreemanDaily: CT: #Lungcancer detection, treatment and research are moving forward rapidly. #WCLC2017 helps keep momentum going. #lcsm
Oliver G. Murphy @ogmurphy1
RT @cpeedell: T4 1.50am in UK! My tea's gone cold. Off to bed. Goodnight to all on #LCSM. Thanks to @BrendonStilesMD for an excellent job a…
Andrea Borondy Kitts @findlungcancer
@BrendonStilesMD lot of comments from people that they found it helpful/impactful to hear patient perspective #lungcancer screening #LCSM #wclc2017
Ben Turner @bentlgerturner
RT @EdenLake: Thank you all for fellowship, support, comraderie and comiseration as always. You make it more bearable. #lcsm
Eden Lake @EdenLake
@JFreemanDaily Id just moved from 1 to early 2 at surgery. Current therapy I am tolerating fairly well, one more round to go before rescan & re-eval #lcsm
#LCSM content from Twitter.